30-day readmission of patients with acute heart failure: a meta-analysis of real-world studies <i>vs.</i> randomized controlled trials_Chinese Journal of Evidence-Based Medicine

Authors：

ZHANG Xuecheng ^1,2 , LIU Yan ¹ , ZHANG Jingjing ^1,2 , CHEN Ying ^1,2 , DAI Hengheng ^1,2 , WAN Siqi ^1,2 , GUAN Zhiyue ^1,2 , HU Mingzhi ^1,2 ,  SHANG Hongcai ¹

1. Chinese Academy of Medical Sciences and Peking Union Medical Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R.China;
2. Beijing University of Chinese Medicine, Beijing 100029, P.R.China;

Corresponding?author：

SHANG Hongcai, Email: shanghongcai@126.com

Keywords：

Real-world study; Randomized controlled trial; Acute heart failure; Readmission rate; Meta-analysis; Systematic review

DOI：

10.7507/1672-2531.202104094

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the difference in 30-day readmission rates among acute heart failure patients between real-world studies vs. randomized controlled trials (RCTs). Methods PubMed, EMbase, The Cochrane Library, CNKI, CBM, VIP and WanFang Data databases were electronically searched to collect clinical studies on 30-day readmission rates in patients with acute heart failure from inception to April 12^th, 2021. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using Stata 16.0 software. Results A total of 33 real-world studies and 11 RCTs involving 106 722 subjects were included. The results of meta-analysis showed that the 30-day heart failure-related readmission rates in the real-world studies and RCTs were 10.8% (95%CI 9.3% to 12.3%) and 6.9% (95%CI 5.3% to 8.4%), respectively. The 30-day all-cause readmission rates in real-world studies and randomized controlled studies were 18.6% (95%CI 15.7% to 21.4%) and 14.2% (95%CI 12.0% to 16.3%), respectively. There were statistically significant differences between two kinds of studies (P<0.05). Conclusions Current evidence suggests that the 30-day heart failure-related and all-cause readmission rates in patients of acute heart failure in real-world studies are significantly higher than those in patients of RCTs. Due to the limited quality and quantity of included studies, more high-quality studies are required to verify the above conclusions.

Citation： ZHANG Xuecheng, LIU Yan, ZHANG Jingjing, CHEN Ying, DAI Hengheng, WAN Siqi, GUAN Zhiyue, HU Mingzhi, SHANG Hongcai. 30-day readmission of patients with acute heart failure: a meta-analysis of real-world studies vs. randomized controlled trials. Chinese Journal of Evidence-Based Medicine, 2021, 21(10): 1203-1210. doi: 10.7507/1672-2531.202104094 Copy

1.	王華, 梁延春. 中國心力衰竭診斷和治療指南 2018. 中華心血管病雜志, 2018, 46(10): 760-789.
2.	Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA, 2010, 303(21): 2141-2147.
3.	宣建偉, 朱水清, 王韶屏, 等. 我國一線城市心力衰竭患者住院費用調查及其影響因素分析. 中國醫療保險, 2017, (12): 52-56.
4.	國家心血管病醫療質量控制中心專家委員會心力衰竭專家工作組. 2020 中國心力衰竭醫療質量控制報告. 中國循環雜志, 2021, 36(3): 221-238.
5.	Dharmarajan K, Hsieh AF, Lin Z, et al. Hospital readmission performance and patterns of readmission: retrospective cohort study of medicare admissions. BMJ, 2013, 347: f6571.
6.	Lim NK, Lee SE, Lee HY, et al. Risk prediction for 30-day heart failure-specific readmission or death after discharge: data from the Korean acute heart failure (KorAHF) registry. J Cardiol, 2019, 73(2): 108-113.
7.	Bensimhon D, Alali SA, Curran L, et al. The use of the reds noninvasive lung fluid monitoring system to assess readiness for discharge in patients hospitalized with acute heart failure: A pilot study. Heart Lung, 2021, 50(1): 59-64.
8.	Woodruff AE, Kelley AM, Hempel CA, et al. Discharge diuretic dose and 30-day readmission rate in acute decompensated heart failure. Ann Pharmacother, 2016, 50(6): 437-445.
9.	石舒原, 趙厚宇, 周慶欣, 等. 真實世界證據與隨機對照試驗: RCT DUPLICATE 項目方法學介紹. 藥物流行病學雜志, 2020, 29(3): 198-205.
10.	Peppercorn JM, Weeks JC, Cook EF, et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet, 2004, 363(9405): 263-270.
11.	Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst, 2006, 98(16): 1108-1117.
12.	?a?layan ?, Goldstein JS, Ayer T, et al. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients. Cancer, 2019, 125(11): 1837-1847.
13.	Prince RM, Atenafu EG, Krzyzanowska MK. Hospitalizations during systemic therapy for metastatic lung cancer: a systematic review of real world vs clinical trial outcomes. JAMA Oncol, 2015, 1(9): 1333-1339.
14.	田磊, 岳彩賓, 管欣, 等. 真實世界研究與隨機對照試驗在臨床實踐及衛生決策中應用的比較. 中國醫院藥學雜志, 2019, 39(3): 274-277.
15.	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
16.	Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (version 5.1.0). The Cochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org.
17.	劉曼, 陳文松, 劉玉秀, 等. 單組率研究含零事件的 Meta 分析方法. 中國循證醫學雜志, 2020, 20(10): 1226-1233.
18.	Bartone C, Saghir S, Menon SG, et al. Comparison of ultrafiltration, nesiritide, and usual care in acute decompensated heart failure. Congest Heart Fail, 2008, 14(6): 298-301.
19.	Basoor A, Doshi NC, Cotant JF, et al. Decreased readmissions and improved quality of care with the use of an inexpensive checklist in heart failure. Congest Heart Fail, 2013, 19(4): 200-206.
20.	Chen L, Ionescu-Ittu R, Romdhani H, et al. Disease management and outcomes in patients hospitalized for acute heart failure in Japan. Cardiol Ther, 2021, 10(1): 211-228.
21.	De Vecchis R, Di Maio M, Di Biase G, et al. Effects of hyponatremia normalization on the short-term mortality and rehospitalizations in patients with recent acute decompensated heart failure: a retrospective study. J Clin Med, 2016, 5(10): 92.
22.	Di Tano G, De Maria R, Gonzini L, et al. The 30-day metric in acute heart failure revisited: data from IN-HF outcome, an Italian nationwide cardiology registry. Eur J Heart Fail, 2015, 17(10): 1032-1041.
23.	Dunlay SM, Griffin JM, Redfield MM, et al. Patient activation in acute decompensated heart failure. J Cardiovasc Nurs, 2017, 32(6): 560-567.
24.	Freda BJ, Knee AB, Braden GL, et al. Effect of transient and sustained acute kidney injury on readmissions in acute decompensated heart failure. Am J Cardiol, 2017, 119(11): 1809-1814.
25.	Fudim M, Sayeed S, Xu H, et al. Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction. Circ Heart Fail, 2020, 13(4): e006645.
26.	Gunton JE, Nandal S, Jones J, et al. Validation of the "doorbell test": a novel functional test of frailty and clinical status after acute decompensated heart failure. Heart Lung Circ, 2020, 29(7): 1054-1062.
27.	He W, Jia J, Chen J, et al. Comparison of prognostic value of red cell distribution width and NT-proBNP for short-term clinical outcomes in acute heart failure patients. Int Heart J, 2014, 55(1): 58-64.
28.	Kitakata H, Kohno T, Kohsaka S, et al. Prognostic implications of early and midrange readmissions after acute heart failure hospitalizations: a report from a Japanese multicenter registry. J Am Heart Assoc, 2020, 9(10): e014949.
29.	Laliberte B, Reed BN, Devabhakthuni S, et al. Observation of patients transitioned to an oral loop diuretic before discharge and risk of readmission for acute decompensated heart failure. J Card Fail, 2017, 23(10): 746-752.
30.	Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean acute heart failure registry (KorAHF). Korean Circ J, 2017, 47(3): 341-353.
31.	Mi?ana G, Bosch MJ, Nú?ez E, et al. Length of stay and risk of very early readmission in acute heart failure. Eur J Intern Med, 2017, 42: 61-66.
32.	Miró ò, Gil V, Xipell C, et al. IMPROV-ED study: outcomes after discharge for an episode of acute-decompensated heart failure and comparison between patients discharged from the emergency department and hospital wards. Clin Res Cardiol, 2017, 106(5): 369-378.
33.	Nael J, Ruggiu M, Bailleul C, et al. Impact of hyperoxia on patients hospitalized in an intensive care unit for acute heart failure. Arch Cardiovasc Dis, 2019, 112(12): 748-753.
34.	Newton PJ, Si S, Reid CM, et al. Survival after an acute heart failure admission. Twelve-month outcomes from the NSW HF snapshot study. Heart Lung Circ, 2020, 29(7): 1032-1038.
35.	Nú?ez J, Bonanad C, Navarro JP, et al. Differential effect of glycosylated hemoglobin value and antidiabetic treatment on the risk of 30-day readmission following a hospitalization for acute heart failure. Rev Esp Cardiol (Engl Ed), 2015, 68(10): 852-860.
36.	Nú?ez J, Comín-Colet J, Mi?ana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail, 2016, 18(7): 798-802.
37.	Oehler A, Kent K, Davis J. Assessment of discharge readiness and readmission risk in patients with acute decompensated heart failure. Am J Cardiol, 2018, 122(12): 2086-2094.
38.	Ogunneye O, Rothberg MB, Friderici J, et al. The association between skilled nursing facility care quality and 30-day readmission rates after hospitalization for heart failure. Am J Med Qual, 2015, 30(3): 205-213.
39.	Okuhara Y, Hirotani S, Ando T, et al. Comparison of salt with low-dose furosemide and carperitide for treating acute decompensated heart failure: a single-center retrospective cohort study. Heart Vessels, 2017, 32(4): 419-427.
40.	Rahhal A, Saad MO, Tawengi K, et al. Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study. BMC Cardiovasc Disord, 2019, 19(1): 127.
41.	Schrager J, Wheatley M, Georgiopoulou V, et al. Favorable bed utilization and readmission rates for emergency department observation unit heart failure patients. Acad Emerg Med, 2013, 20(6): 554-561.
42.	Selim AM, Mazurek JA, Iqbal M, et al. Mortality and readmission rates in patients hospitalized for acute decompensated heart failure: a comparison between cardiology and general-medicine service outcomes in an underserved population. Clin Cardiol, 2015, 38(3): 131-138.
43.	Sudharshan S, Novak E, Hock K, et al. Use of Biomarkers to predict readmission for congestive heart failure. Am J Cardiol, 2017, 119(3): 445-451.
44.	Tabit CE, Coplan MJ, Spencer KT, et al. Cardiology consultation in the emergency department reduces re-hospitalizations for low-socioeconomic patients with acute decompensated heart failure. Am J Med, 2017, 130(9): 1112-1117.
45.	Uthamalingam S, Gurm GS, Daley M, et al. Usefulness of acute delirium as a predictor of adverse outcomes in patients >65 years of age with acute decompensated heart failure. Am J Cardiol, 2011, 108(3): 402-408.
46.	Yaku H, Kato T, Morimoto T, et al. Risk factors and clinical outcomes of functional decline during hospitalisation in very old patients with acute decompensated heart failure: an observational study. BMJ Open, 2020, 10(2): e032674.
47.	杜亭亭, 苗雨陽, 劉欣, 等. 血漿腦鈉肽對老年急性失代償性心力衰竭患者再入院的預測價值. 中華老年醫學雜志, 2018, 37(11): 1204-1207.
48.	馬喬娟, 劉超, 張軍, 等. 急性失代償性心力衰竭患者血清鈉離子和尿酸水平對短期預后的預測價值. 中國心血管雜志, 2018, 23(6): 473-476.
49.	張蘭芳, 賈辛未, 趙淑君, 等. 血糖水平升高對不伴有糖尿病的老年急性心力衰竭患者心功能及預后的影響. 中國醫藥, 2020, 15(5): 650-653.
50.	Aliti GB, Rabelo ER, Clausell N, et al. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern Med, 2013, 173(12): 1058-1064.
51.	Bell SP, Schnipper JL, Goggins K, et al. Effect of pharmacist counseling intervention on health care utilization following hospital discharge: a randomized control trial. J Gen Intern Med, 2016, 31(5): 470-477.
52.	Cleland JG, Chiswell K, Teerlink JR, et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function (PROTECT) study. Circ Heart Fail, 2014, 7(1): 76-87.
53.	Fudim M, O'Connor CM, Dunning A, et al. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. Eur J Heart Fail, 2018, 20(2): 304-314.
54.	Gottlieb SS, Givertz MM, Metra M, et al. The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. J Card Fail, 2010, 16(9): 714-719.
55.	Hummel SL, Karmally W, Gillespie BW, et al. Home-delivered meals postdischarge from heart failure hospitalization. Circ Heart Fail, 2018, 11(8): e004886.
56.	M?ckel M, de Boer RA, Slagman AC, et al. Improve management of acute heart failure with procalcitonin in Europe: results of the randomized clinical trial IMPACT EU biomarkers in cardiology (BIC) 18. Eur J Heart Fail, 2020, 22(2): 267-275.
57.	Packer M, O'Connor C, McMurray JJV, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med, 2017, 376(20): 1956-1964.
58.	Sepehrvand N, Alemayehu W, Rowe BH, et al. High vs. low oxygen therapy in patients with acute heart failure: HiLo-HF pilot trial. ESC Heart Fail, 2019, 6(4): 667-677.
59.	Vaishnav J, Chasler JE, Lee YJ, et al. Highest obesity category associated with largest decrease in n-terminal pro-b-type natriuretic peptide in patients hospitalized with heart failure with preserved ejection fraction. J Am Heart Assoc, 2020, 9(15): e015738.
60.	Wang YB, Hao GZ, Jiang YF, et al. Effects of levosimendan on right ventricular function in patients with acute decompensated heart failure. Acta Cardiol Sin, 2019, 35(6): 585-591.
61.	Laursen PN, Holmvang L, L?nborg J, et al. Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study. Am Heart J, 2018, 204: 128-138.
62.	Templeton AJ, Vera-Badillo FE, Wang L, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol, 2013, 24(12): 2972-2977.
63.	Sorbye H, Pfeiffer P, Cavalli-Bj?rkman N, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer, 2009, 115(20): 4679-4687.
64.	王海燕, 李美英. 我國藥品, 醫療器械不良反應監測情況概述以及對構建特殊食品安全性監測體系的啟示. 中國食品藥品監管, 2020, (7): 32-51.
65.	賀佳. 臨床試驗中藥物安全性的統計學考慮. 世界科學技術-中醫藥現代化, 2017, 19(7): 1089-1096.
66.	Schoenmakers TW, Teichert M, Wensing M, et al. Evaluation of potentially drug-related patient-reported common symptoms assessed during clinical medication reviews: a cross-sectional observational study. Drug Saf, 2017, 40(5): 419-430.
67.	Athar MW, Record JD, Martire C, et al. The effect of a personalized approach to patient education on heart failure self-management. J Pers Med, 2018, 8(4): 39.
68.	Hu J, Wan Q, Zhang Y, et al. Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial. BMC Cardiovasc Disord, 2020, 20(1): 447.
69.	Patel B, Prousi G, Shah M, et al. Thirty-day readmission rate in acute heart failure patients discharged against medical advice in a matched cohort study. Mayo Clin Proc, 2018, 93(10): 1397-1403.

1. 王華, 梁延春. 中國心力衰竭診斷和治療指南 2018. 中華心血管病雜志, 2018, 46(10): 760-789.
2. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA, 2010, 303(21): 2141-2147.
3. 宣建偉, 朱水清, 王韶屏, 等. 我國一線城市心力衰竭患者住院費用調查及其影響因素分析. 中國醫療保險, 2017, (12): 52-56.
4. 國家心血管病醫療質量控制中心專家委員會心力衰竭專家工作組. 2020 中國心力衰竭醫療質量控制報告. 中國循環雜志, 2021, 36(3): 221-238.
5. Dharmarajan K, Hsieh AF, Lin Z, et al. Hospital readmission performance and patterns of readmission: retrospective cohort study of medicare admissions. BMJ, 2013, 347: f6571.
6. Lim NK, Lee SE, Lee HY, et al. Risk prediction for 30-day heart failure-specific readmission or death after discharge: data from the Korean acute heart failure (KorAHF) registry. J Cardiol, 2019, 73(2): 108-113.
7. Bensimhon D, Alali SA, Curran L, et al. The use of the reds noninvasive lung fluid monitoring system to assess readiness for discharge in patients hospitalized with acute heart failure: A pilot study. Heart Lung, 2021, 50(1): 59-64.
8. Woodruff AE, Kelley AM, Hempel CA, et al. Discharge diuretic dose and 30-day readmission rate in acute decompensated heart failure. Ann Pharmacother, 2016, 50(6): 437-445.
9. 石舒原, 趙厚宇, 周慶欣, 等. 真實世界證據與隨機對照試驗: RCT DUPLICATE 項目方法學介紹. 藥物流行病學雜志, 2020, 29(3): 198-205.
10. Peppercorn JM, Weeks JC, Cook EF, et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet, 2004, 363(9405): 263-270.
11. Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst, 2006, 98(16): 1108-1117.
12. ?a?layan ?, Goldstein JS, Ayer T, et al. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients. Cancer, 2019, 125(11): 1837-1847.
13. Prince RM, Atenafu EG, Krzyzanowska MK. Hospitalizations during systemic therapy for metastatic lung cancer: a systematic review of real world vs clinical trial outcomes. JAMA Oncol, 2015, 1(9): 1333-1339.
14. 田磊, 岳彩賓, 管欣, 等. 真實世界研究與隨機對照試驗在臨床實踐及衛生決策中應用的比較. 中國醫院藥學雜志, 2019, 39(3): 274-277.
15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (version 5.1.0). The Cochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org.
17. 劉曼, 陳文松, 劉玉秀, 等. 單組率研究含零事件的 Meta 分析方法. 中國循證醫學雜志, 2020, 20(10): 1226-1233.
18. Bartone C, Saghir S, Menon SG, et al. Comparison of ultrafiltration, nesiritide, and usual care in acute decompensated heart failure. Congest Heart Fail, 2008, 14(6): 298-301.
19. Basoor A, Doshi NC, Cotant JF, et al. Decreased readmissions and improved quality of care with the use of an inexpensive checklist in heart failure. Congest Heart Fail, 2013, 19(4): 200-206.
20. Chen L, Ionescu-Ittu R, Romdhani H, et al. Disease management and outcomes in patients hospitalized for acute heart failure in Japan. Cardiol Ther, 2021, 10(1): 211-228.
21. De Vecchis R, Di Maio M, Di Biase G, et al. Effects of hyponatremia normalization on the short-term mortality and rehospitalizations in patients with recent acute decompensated heart failure: a retrospective study. J Clin Med, 2016, 5(10): 92.
22. Di Tano G, De Maria R, Gonzini L, et al. The 30-day metric in acute heart failure revisited: data from IN-HF outcome, an Italian nationwide cardiology registry. Eur J Heart Fail, 2015, 17(10): 1032-1041.
23. Dunlay SM, Griffin JM, Redfield MM, et al. Patient activation in acute decompensated heart failure. J Cardiovasc Nurs, 2017, 32(6): 560-567.
24. Freda BJ, Knee AB, Braden GL, et al. Effect of transient and sustained acute kidney injury on readmissions in acute decompensated heart failure. Am J Cardiol, 2017, 119(11): 1809-1814.
25. Fudim M, Sayeed S, Xu H, et al. Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction. Circ Heart Fail, 2020, 13(4): e006645.
26. Gunton JE, Nandal S, Jones J, et al. Validation of the "doorbell test": a novel functional test of frailty and clinical status after acute decompensated heart failure. Heart Lung Circ, 2020, 29(7): 1054-1062.
27. He W, Jia J, Chen J, et al. Comparison of prognostic value of red cell distribution width and NT-proBNP for short-term clinical outcomes in acute heart failure patients. Int Heart J, 2014, 55(1): 58-64.
28. Kitakata H, Kohno T, Kohsaka S, et al. Prognostic implications of early and midrange readmissions after acute heart failure hospitalizations: a report from a Japanese multicenter registry. J Am Heart Assoc, 2020, 9(10): e014949.
29. Laliberte B, Reed BN, Devabhakthuni S, et al. Observation of patients transitioned to an oral loop diuretic before discharge and risk of readmission for acute decompensated heart failure. J Card Fail, 2017, 23(10): 746-752.
30. Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean acute heart failure registry (KorAHF). Korean Circ J, 2017, 47(3): 341-353.
31. Mi?ana G, Bosch MJ, Nú?ez E, et al. Length of stay and risk of very early readmission in acute heart failure. Eur J Intern Med, 2017, 42: 61-66.
32. Miró ò, Gil V, Xipell C, et al. IMPROV-ED study: outcomes after discharge for an episode of acute-decompensated heart failure and comparison between patients discharged from the emergency department and hospital wards. Clin Res Cardiol, 2017, 106(5): 369-378.
33. Nael J, Ruggiu M, Bailleul C, et al. Impact of hyperoxia on patients hospitalized in an intensive care unit for acute heart failure. Arch Cardiovasc Dis, 2019, 112(12): 748-753.
34. Newton PJ, Si S, Reid CM, et al. Survival after an acute heart failure admission. Twelve-month outcomes from the NSW HF snapshot study. Heart Lung Circ, 2020, 29(7): 1032-1038.
35. Nú?ez J, Bonanad C, Navarro JP, et al. Differential effect of glycosylated hemoglobin value and antidiabetic treatment on the risk of 30-day readmission following a hospitalization for acute heart failure. Rev Esp Cardiol (Engl Ed), 2015, 68(10): 852-860.
36. Nú?ez J, Comín-Colet J, Mi?ana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail, 2016, 18(7): 798-802.
37. Oehler A, Kent K, Davis J. Assessment of discharge readiness and readmission risk in patients with acute decompensated heart failure. Am J Cardiol, 2018, 122(12): 2086-2094.
38. Ogunneye O, Rothberg MB, Friderici J, et al. The association between skilled nursing facility care quality and 30-day readmission rates after hospitalization for heart failure. Am J Med Qual, 2015, 30(3): 205-213.
39. Okuhara Y, Hirotani S, Ando T, et al. Comparison of salt with low-dose furosemide and carperitide for treating acute decompensated heart failure: a single-center retrospective cohort study. Heart Vessels, 2017, 32(4): 419-427.
40. Rahhal A, Saad MO, Tawengi K, et al. Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study. BMC Cardiovasc Disord, 2019, 19(1): 127.
41. Schrager J, Wheatley M, Georgiopoulou V, et al. Favorable bed utilization and readmission rates for emergency department observation unit heart failure patients. Acad Emerg Med, 2013, 20(6): 554-561.
42. Selim AM, Mazurek JA, Iqbal M, et al. Mortality and readmission rates in patients hospitalized for acute decompensated heart failure: a comparison between cardiology and general-medicine service outcomes in an underserved population. Clin Cardiol, 2015, 38(3): 131-138.
43. Sudharshan S, Novak E, Hock K, et al. Use of Biomarkers to predict readmission for congestive heart failure. Am J Cardiol, 2017, 119(3): 445-451.
44. Tabit CE, Coplan MJ, Spencer KT, et al. Cardiology consultation in the emergency department reduces re-hospitalizations for low-socioeconomic patients with acute decompensated heart failure. Am J Med, 2017, 130(9): 1112-1117.
45. Uthamalingam S, Gurm GS, Daley M, et al. Usefulness of acute delirium as a predictor of adverse outcomes in patients >65 years of age with acute decompensated heart failure. Am J Cardiol, 2011, 108(3): 402-408.
46. Yaku H, Kato T, Morimoto T, et al. Risk factors and clinical outcomes of functional decline during hospitalisation in very old patients with acute decompensated heart failure: an observational study. BMJ Open, 2020, 10(2): e032674.
47. 杜亭亭, 苗雨陽, 劉欣, 等. 血漿腦鈉肽對老年急性失代償性心力衰竭患者再入院的預測價值. 中華老年醫學雜志, 2018, 37(11): 1204-1207.
48. 馬喬娟, 劉超, 張軍, 等. 急性失代償性心力衰竭患者血清鈉離子和尿酸水平對短期預后的預測價值. 中國心血管雜志, 2018, 23(6): 473-476.
49. 張蘭芳, 賈辛未, 趙淑君, 等. 血糖水平升高對不伴有糖尿病的老年急性心力衰竭患者心功能及預后的影響. 中國醫藥, 2020, 15(5): 650-653.
50. Aliti GB, Rabelo ER, Clausell N, et al. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern Med, 2013, 173(12): 1058-1064.
51. Bell SP, Schnipper JL, Goggins K, et al. Effect of pharmacist counseling intervention on health care utilization following hospital discharge: a randomized control trial. J Gen Intern Med, 2016, 31(5): 470-477.
52. Cleland JG, Chiswell K, Teerlink JR, et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function (PROTECT) study. Circ Heart Fail, 2014, 7(1): 76-87.
53. Fudim M, O'Connor CM, Dunning A, et al. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. Eur J Heart Fail, 2018, 20(2): 304-314.
54. Gottlieb SS, Givertz MM, Metra M, et al. The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. J Card Fail, 2010, 16(9): 714-719.
55. Hummel SL, Karmally W, Gillespie BW, et al. Home-delivered meals postdischarge from heart failure hospitalization. Circ Heart Fail, 2018, 11(8): e004886.
56. M?ckel M, de Boer RA, Slagman AC, et al. Improve management of acute heart failure with procalcitonin in Europe: results of the randomized clinical trial IMPACT EU biomarkers in cardiology (BIC) 18. Eur J Heart Fail, 2020, 22(2): 267-275.
57. Packer M, O'Connor C, McMurray JJV, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med, 2017, 376(20): 1956-1964.
58. Sepehrvand N, Alemayehu W, Rowe BH, et al. High vs. low oxygen therapy in patients with acute heart failure: HiLo-HF pilot trial. ESC Heart Fail, 2019, 6(4): 667-677.
59. Vaishnav J, Chasler JE, Lee YJ, et al. Highest obesity category associated with largest decrease in n-terminal pro-b-type natriuretic peptide in patients hospitalized with heart failure with preserved ejection fraction. J Am Heart Assoc, 2020, 9(15): e015738.
60. Wang YB, Hao GZ, Jiang YF, et al. Effects of levosimendan on right ventricular function in patients with acute decompensated heart failure. Acta Cardiol Sin, 2019, 35(6): 585-591.
61. Laursen PN, Holmvang L, L?nborg J, et al. Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study. Am Heart J, 2018, 204: 128-138.
62. Templeton AJ, Vera-Badillo FE, Wang L, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol, 2013, 24(12): 2972-2977.
63. Sorbye H, Pfeiffer P, Cavalli-Bj?rkman N, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer, 2009, 115(20): 4679-4687.
64. 王海燕, 李美英. 我國藥品, 醫療器械不良反應監測情況概述以及對構建特殊食品安全性監測體系的啟示. 中國食品藥品監管, 2020, (7): 32-51.
65. 賀佳. 臨床試驗中藥物安全性的統計學考慮. 世界科學技術-中醫藥現代化, 2017, 19(7): 1089-1096.
66. Schoenmakers TW, Teichert M, Wensing M, et al. Evaluation of potentially drug-related patient-reported common symptoms assessed during clinical medication reviews: a cross-sectional observational study. Drug Saf, 2017, 40(5): 419-430.
67. Athar MW, Record JD, Martire C, et al. The effect of a personalized approach to patient education on heart failure self-management. J Pers Med, 2018, 8(4): 39.
68. Hu J, Wan Q, Zhang Y, et al. Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial. BMC Cardiovasc Disord, 2020, 20(1): 447.
69. Patel B, Prousi G, Shah M, et al. Thirty-day readmission rate in acute heart failure patients discharged against medical advice in a matched cohort study. Mayo Clin Proc, 2018, 93(10): 1397-1403.

Previous Article
Prevalence and risk factors of chronic pain after cesarean section: a systematic review
Next Article
Data integrity of randomized controlled trial in TCM

Chinese Journal of Evidence-Based Medicine

30-day readmission of patients with acute heart failure: a meta-analysis of real-world studies vs. randomized controlled trials

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content